D. Ge, J. Fellay, A. Thompson, J. Simon, K. Shianna et al., Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance, Nature, vol.18, issue.7262, pp.399-401
DOI : 10.1038/nature08309

S. Deuffic?burban, P. Mathurin, S. Pol, C. Larsen, F. Roudot?thoraval et al., The availability od direct acting antivirals in 2012 : a french model based analysis of the increased number of patients traeted for chronic HCV infection, Gut, 2011.

S. Deuffic?burban, P. Deltenre, M. Buti, T. Stroffolini, J. Parkes et al., 122 HCV BURDEN IN EUROPE: IMPACT OF NATIONAL TREATMENT PRACTICES ON FUTURE HCV-RELATED MORBIDITY AND MORTALITY THROUGH A MODELING APPROACH, Journal of Hepatology, vol.54, p.54
DOI : 10.1016/S0168-8278(11)60124-4

L. Fartoux, O. Chazouilleres, D. Wendum, R. Poupon, and L. Serfaty, Impact of steatosis on progression of fibrosis in patients with mild hepatitis C, Hepatology, vol.34, issue.Suppl 1, pp.82-89, 2005.
DOI : 10.1002/hep.20519

A. Craxi, EASL Clinical Practice Guidelines: Management of hepatitis C virus infection, 2011.

M. Bourlière, D. Ouzan, M. Rosenheim, M. Doffoël, P. Marcellin et al., Peg interferonalfa?2a plus ribavirin for chronic hepatitis C in a real life setting : the Hepatys French cohort, 20032007.

M. Shiffman, C. Morishima, J. Dienstag, K. Lindsay, J. Hoefs et al., Effect of HCV RNA suppression during peginterferon alfa?2a maintenance therapy on clinical outcomes in the HALT?C trial. 137:1986?94. effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy, pp.1618-1646

J. Mchuntchinson, J. Ware, . Jr, and M. Bayliss, The effects of interferon alfa 2b in combination with ribavirin on health related quality of life and work productivity, J Hepatology, 2001.

K. Reddy, M. Shiffman, T. Morgan, S. Zeuzem, S. Hadziyannis et al., Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment, Clinical Gastroenterology and Hepatology, vol.5, issue.1, pp.124-133
DOI : 10.1016/j.cgh.2006.10.008

J. Mchuntchinson, M. Manns, and K. Patel, Adherence to combination therapy enhances sustained response in genotype?1?infected patients with chronic hepatitis C. Gastroenterolgy, 2002.

C. Hezode, N. Forestier, G. Dusheiko, P. Ferenci, S. Pol et al., Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection, New England Journal of Medicine, vol.360, issue.18, pp.1839-50
DOI : 10.1056/NEJMoa0807650

URL : https://hal.archives-ouvertes.fr/inserm-00385235

P. Kwo, E. Lawitz, J. Mccone, E. Schiff, J. Vierling et al., Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial, The Lancet, vol.376, issue.9742, pp.705-721
DOI : 10.1016/S0140-6736(10)60934-8

I. Jacobson, J. Mchutchison, G. Dusheiko, D. Bisceglie, A. Reddy et al., ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection, pp.2405-2421

F. Poordad, J. Mccone, J. Bacon, B. Bruno, S. Manns et al., Boceprevir for Untreated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1195-206
DOI : 10.1056/NEJMoa1010494

URL : https://hal.archives-ouvertes.fr/hal-00867494

I. Jacobson, I. Catlett, P. Marcellin, N. Bzowej, A. Muir et al., Telaprevir substantially improved SVR rates accross all IL28B genotypes in the advance trial, p.543

F. Poordad, J. Bronowicki, S. Gordon, S. Zeuzem, I. Jacobson et al., IL28B polymorphisms predicts virological response in patients with hepatitis C genotype 1 treated with boceprevir combination therapy, p.6

J. Mchutchison, M. Manns, A. Muir, N. Terrault, I. Jacobson et al., Telaprevir for Previously Treated Chronic HCV Infection, New England Journal of Medicine, vol.362, issue.14, pp.1292-303
DOI : 10.1056/NEJMoa0908014

S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago et al., REALIZE Study Team Telaprevir for retreatment of HCV infection, pp.2417-2445

B. Bacon, S. Gordon, E. Lawitz, P. Marcellin, J. Vierling et al., Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1207-1224
DOI : 10.1056/NEJMoa1009482

S. Bruno, J. Vierling, R. Esteban, L. Nyberg, H. Tanno et al., 7 BOCEPREVIR IN ADDITION TO STANDARD OF CARE ENHANCED SVR IN HEPATITIS C VIRUS (HCV) GENOTYPE-1 WITH ADVANCED FIBROSIS/CIRRHOSIS: SUBGROUP ANALYSIS OF SPRINT-2 AND RESPOND-2 STUDIES, Journal of Hepatology, vol.54, p.4
DOI : 10.1016/S0168-8278(11)60009-3

T. Berg, P. Andreone, S. Pol, S. Roberts, Z. Younossi et al., Predictors of virologic response with telaprevir?based combination treatment in HCV genotype 1?infected patients with prior peg?ifn/ribavirin failure : post?hoc analysis of the phase III REALIZE study, p.32

S. Pol, J. Aerssens, S. Zeuzem, P. Andreone, E. Lawitz et al., Similar SVR rates in IL28B CC, CT or TT prior relapser, partial or null?responder patients treated with telaprevir/peg? IFN/ribavirin : retrospective analysis of the REALIZE study, p.6

M. Sulkowski, K. Reddy, N. Afdhal, D. Bisceglie, A. Zeuzem et al., Anemia has no effect on efficacy outcomes in treatment?naive patients who received telaprevir?based regimen in ADVANCE and ILLUMINATE phase 3 studies, p.195

M. Sulkowski, F. Poordad, M. Manns, J. Bronowicki, K. Reddy et al., Anemia during treatment with peginterferon alfa?2B/ribavirin with or without boceprevir is associated with higherSVR rates : analysis of previously untreated and previous?treatment?failure patients, p.194

N. Afdhal, D. Dieterich, P. Pockros, E. Schiff, M. Shiffman et al., Epoetin alfa maintains ribavirin dose in HCV?infected patients: a prospective, double?blind, randomized controlled study, pp.1302-1313

A. Cohorte, Résumé du rapport de synthèse N°3, 2011.

K. Thorlund, E. Druyts, E. Khoury, and C. , Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection, ClinicoEconomics and Outcomes Research, pp.349-359, 2012.

C. Cammà, S. Petta, and G. Cabibb, Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C, Journal of Hepatology, vol.59, issue.4, pp.658-666, 2013.
DOI : 10.1016/j.jhep.2013.05.019

M. Mims, Prescription drug database and drug prescribing guide (2012) Disponible sur

C. Cooper, E. Druyts, and K. Thorlund, Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta?analysis, Therapy Clinical Risk Manager, vol.8, pp.105-130

C. Cooper, R. Lester, and K. Thorlund, Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis, QJM, vol.106, issue.2, 2012.
DOI : 10.1093/qjmed/hcs214

S. Hill, B. Khoo, N. Simmons, and . Ford, What is the minimum cost per person to cure HCV? 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 2013.

J. Vierling, S. Flamm, S. Gordon, E. Lawitz, J. Bronowicki et al., Efficacy of boceprevir in prior null responders tp Peg?interferon?Ribavirin : the PROVIDE study, p.931